Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1600 1614 1621 1629 1691
This examiner grants 61% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18818731 | BIOMARKERS USEFUL IN THE TREATMENT OF SUBJECTS HAVING DISEASES OF THE EYE | Non-Final OA | The Johns Hopkins University |
| 18561444 | FORMULATIONS OF 3-((3-(4-(2-(ISOBUTYLSULFONYL)PHENOXY)-3-(TRIFLUOROMETHYL)PHENYL)-1,2,4-OXADIAZOL-5-YL)METHYL)-5,5-DIMETHYL-1-(2-MORPHOLINOETHYL)IMIDAZOLIDINE-2,4-DIONE | Non-Final OA | Novartis AG |
| 18019972 | Pharmaceuticals for Treating or Preventing Nidoviruses and Picornaviruses | Final Rejection | The University of Chicago |
| 18790141 | SMALL MOLECULE INHIBITORS OF GPCR GPR68 AND RELATED RECEPTORS FOR TREATING CANCER, GLIOBLASTOMA, AND OTHER INDICATIONS | Non-Final OA | UNIVERSITY OF MARYLAND, BALTIMORE |
| 18769264 | BENZOQUINOLONE INHIBITORS OF VMAT2 | Non-Final OA | Auspex Pharmaceuticals, Inc. |
| 18792993 | Composition and Methods for the Prevention of Aminoglycoside Toxicity | Non-Final OA | Ting Therapeutics, Inc |
| 18816461 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR ANESTHESIOLOGICAL APPLICATIONS | Non-Final OA | Harrow IP, LLC |
| 18731965 | Compositions And Methods For Reducing Major Adverse Cardiovascular Events | Non-Final OA | Nalpropion Pharmaceuticals LLC |
| 18002116 | IRAK DEGRADERS AND USES THEREOF | Non-Final OA | Kymera Therapeutics, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy